Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

10.10.13	Global Distribution Agreements, New Clinical Study Results, FDA Announcements, and Earnings Schedules - Research Report on Life Technologies, GW, Novartis, Salix, and Mallinckrodt (PR Newswire)
06.10.13	Novartis Study Shows Omalizumab Effective In Severe Form Of Chronic Skin Disease (RTTNews)
04.10.13	Novartis: Data Shows Continued Treatment With Gilenya Reduced Brain Volume Loss (RTTNews)
04.10.13	Novartis Reports Four-year Data On Gilenya - Quick Facts (RTTNews)
03.10.13	Novartis Reports Results From Secukinumab Phase III FIXTURE Study - Quick Facts (RTTNews)
02.10.13	MorphoSys To Receive Clinical Milestone Payment From Novartis - Quick Facts (RTTNews)
01.10.13	Pharmaceutical Companies Announce Trial Results, and Achieve New Contracts, Regulatory Approvals, and Positive Opinion - Research Report on Eli Lilly, Pfizer, Novartis, Sanofi, and AstraZeneca (PR Newswire)
30.09.13	Presentation, Licensing Agreement, Trial Milestone, Positive Opinion, and Trade Name Acceptance - Research Report on Pfizer, Allergan, Novartis, AstraZeneca, and Rockwell Medical (PR Newswire)
30.09.13	Novartis To Reveal Phase III Results From Dermatology Portfolio - Quick Facts (RTTNews)
27.09.13	Novartis: Lucentis Data Confirms Transformational Efficacy, Safety Profile (RTTNews)
25.09.13	Pre-Market Review: Dendreon Corp., Stryker Corp., Novartis AG, and Repros Therapeutics Inc. (PR Newswire)
25.09.13	Novartis Confirms Long Term Benefits Of Gilenya In Multiple Sclerosis (RTTNews)
23.09.13	Novartis To Support Power Of One Campaign - Quick Facts (RTTNews)
23.09.13	Novartis' QVA149 Gains EC Approval For COPD Patients In Europe & Japan (RTTNews)
19.09.13	Novartis Updates On Global Research Program - Quick Facts (RTTNews)
18.09.13	Clinical Trial Results, Licensing Agreements, Breakthrough Research and Development Programs - Research Report on Pfizer, Merck, Rockwell Medical, GlaxoSmithKline, and Novartis (PR Newswire)
17.09.13	Critical Alerts For First Solar, Novartis, Boston Beer Company, SAP, and Dish Network Released By InvestorsObserver (PR Newswire)
17.09.13	Clinical Trial Updates, Appointments, FDA Acknowledgments and Qualifications - Research Report on Novartis, Endo, The Medicines Company, United Therapeutics, and Forest (PR Newswire)
10.09.13	FDA and EMA Submissions, Partnerships, Milestones, Participation Withdrawals, and Prequalifications - Research Report on Johnson & Johnson, Novartis, AstraZeneca, Astex Pharmaceuticals, and Sanofi (PR Newswire)
09.09.13	Novartis Says Data From Ultibro Breezhaler Studies For COPD Shows Improvement (RTTNews)
06.09.13	Novartis, Regenerex Ink Licensing, Research Collaboration - Quick Facts (RTTNews)
03.09.13	Novartis' Ilaris Gets EU Approval For Juvenile Idiopathic Arthritis - Update (RTTNews)
03.09.13	Novartis Gets EU Approval For Ilaris In Systemic Juvenile Idiopathic Arthritis (RTTNews)
02.09.13	Novartis: RLX030 Found Effective Across Multiple Subgroups Of Heart Patients (RTTNews)
02.09.13	Novartis: RLX030 Improved Symptoms, Mortality In Heart Patients (RTTNews)
02.09.13	Acquisitions, Topline Results, New Board Members, Events, and Product Milestones - Research Report on Johnson & Johnson, Sanofi, Lilly, AbbVie, and Novartis (PR Newswire)
20.08.13	Pre-Market Analysis: Dendreon Corp., Stryker Corp., Novartis AG, and Repros Therapeutics Inc. (PR Newswire)
20.08.13	Novartis Gets FDA Breakthrough Therapy Designation For BYM338 For SIBM (RTTNews)
19.08.13	Drug Approvals, Clinical Trials, Awards, Offerings, and Earnings - Research Report on J&J, Sanofi, Novartis, BioScrip, and Pacira (PR Newswire)
15.08.13	Novartis: Bexsero Approved In Australia To Protect Against MenB Disease (RTTNews)
14.08.13	Licenses, Phase III Trial Initiation and Results, and Investments - Research Report on Johnson & Johnson, Sanofi, AstraZeneca, Novartis, and GSK (PR Newswire)
07.08.13	Novartis: Phase III HCC Trial With Afinitor Fails To Meet Primary Endpoint (RTTNews)
02.08.13	Novartis Says FDA Expands Age Indication For Meningococcal Vaccine Menveo (RTTNews)
26.07.13	Novartis Receives Postive Opinion For Ilaris From European Medicines Agency (RTTNews)
26.07.13	Mylan Confirms First-to-File Patent Challenge Regarding BANZEL - Quick Facts (RTTNews)
24.07.13	UK JCVI Not Recommends Novartis's Meningitis B Vaccine Bexsero For Immunization (RTTNews)
22.07.13	Successful Integrations, Growth Brands, and Pipeline Innovations Boost Revenue Growth - Research Report on Johnson & Johnson, Abbott, St. Jude Medical, Lilly, and Novartis (PR Newswire)
17.07.13	Novartis Q2 Profit Declines, But Lifts Full-year View (RTTNews)
17.07.13	Novartis Q2 Profit Down; Updates View (RTTNews)
08.07.13	Novartis Says Secukinumab Is Superior To Enbrel In Psoriasis, Meets Endpoints (RTTNews)
08.07.13	Novartis: AIN457 Shows Superiority To Enbrel In Phase III Psoriasis Trial (RTTNews)
05.07.13	Novartis' Lucentis Approved In EU For Myopic Choroidal Neovascularization (RTTNews)
23.09.09	BioTime, Inc. to Form Asian Subsidiary (Businesswire)
02.06.08	Early Data Presented at ASCO Show Potential Of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments (PR Newswire)
19.05.08	RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer (PR Newswire)
15.04.08	FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment (PR Newswire)
31.03.08	Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients (PR Newswire)
10.03.08	VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy (PR Newswire)
28.02.08	Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy (PR Newswire)
12.12.07	Once-Daily Exjade(R) Shown to Remove Toxic Iron From the Heart and Liver, According to Data Presented at ASH (PR Newswire)
12.12.07	Once-Daily Exjade(R) Shown to Remove Toxic Iron From the Heart and Liver, According to Data Presented at ASH (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	28.46	2.63 %	K V
Swiss Life Hldg	712.60	1.86 %	K V
Part Grp Hldg	1’245.50	1.26 %	K V
Zurich Insur Gr	545.00	1.15 %	K V
Swiss Re	132.70	1.14 %	K V
Givaudan	3’945.00	-0.53 %	K V
Geberit	511.20	-0.66 %	K V
Alcon	76.38	-0.68 %	K V
Sika	212.90	-1.34 %	K V
CieFinRichemont	134.25	-2.65 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt